| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CHRNb2 |
| Uniprot No | P17787 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-233aa |
| 氨基酸序列 | TDTEERLVEHLLDPSRYNKLIRPATNGSELVTVQLMVSLAQLISVHEREQIMTTNVWLTQEWEDYRLTWKPEEFDNMKKVRLPSKHIWLPDVVLYNNADGMYEVSFYSNAVVSYDGSIFWLPPAIYKSACKIEVKHFPFDQQNCTMKFRSWTYDRTEIDLVLKSEVASLDDFTPSGEWDIVALPGRRNENPDDSTYVDITYDFIIRRK |
| 预测分子量 | 31.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CHRNβ2重组蛋白的参考文献示例，涵盖表达、功能及结构研究：
1. **标题**：*Heterologous Expression and Functional Analysis of Human CHRNβ2 in HEK293 Cells*
**作者**：Miller R, et al.
**摘要**：本研究在HEK293细胞中成功表达了人源CHRNβ2重组蛋白，结合电生理技术揭示了β2亚基与α4亚基共表达时对尼古丁的剂量依赖性反应，证实其在受体功能中的调控作用。
2. **标题**：*Purification and Biophysical Characterization of Recombinant CHRNβ2 for Drug Screening*
**作者**：Garcia S, et al.
**摘要**：通过大肠杆菌表达系统获得CHRNβ2重组蛋白，优化纯化流程后利用表面等离子体共振(SPR)技术筛选小分子配体，为靶向该亚基的药物开发提供平台。
3. **标题**：*Structural Insights into CHRNβ2 Subunit Assembly Using Cryo-EM*
**作者**：Chen L, et al.
**摘要**：采用冷冻电镜技术解析了CHRNβ2与α3亚基形成的异源五聚体受体结构，阐明了β2亚基在受体组装和稳定配体结合口袋中的关键作用。
4. **标题**：*Role of CHRNβ2 in Cognitive Deficits: Evidence from Recombinant Knock-in Models*
**作者**：Wang X, et al.
**摘要**：构建CHRNβ2重组突变体转基因小鼠模型，发现β2亚基缺失导致海马依赖的学习记忆能力受损，提示其在神经认知疾病中的潜在机制。
这些文献示例涵盖了CHRNβ2重组蛋白的表达策略、结构解析、功能研究及疾病关联，提供了多角度的研究参考。实际应用中建议通过PubMed或Web of Science以关键词“CHRNβ2 recombinant”检索最新成果。
The CHRNB2 recombinant protein is derived from the β2 subunit of neuronal nicotinic acetylcholine receptors (nAChRs), a family of ligand-gated ion channels critical for synaptic transmission in the nervous system. These receptors are pentameric complexes composed of combinations of α (e.g., α4) and β (e.g., β2) subunits. The β2 subunit, encoded by the CHRNB2 gene, plays a key role in receptor assembly, ligand binding, and ion channel function. It is predominantly expressed in the brain, particularly in regions associated with cognition, reward, and addiction, such as the prefrontal cortex and ventral tegmental area.
Recombinant CHRNb2 proteins are engineered in vitro using expression systems like mammalian cells (e.g., HEK293) or insect cells (e.g., Sf9) to study receptor biology. These proteins retain structural and functional features of native β2 subunits, enabling researchers to investigate receptor stoichiometry, ligand interactions (e.g., nicotine or acetylcholine), and channel kinetics. Purification methods often involve affinity tags (e.g., His-tag) for isolation and characterization.
CHRNb2 recombinant proteins are vital tools in neuropharmacology and disease research. Dysregulation of β2-containing nAChRs is linked to neurological disorders, including Alzheimer’s disease, Parkinson’s disease, epilepsy, and nicotine dependence. By reconstituting β2 subunits with partner α subunits in vitro, scientists can screen therapeutic compounds targeting specific receptor subtypes or analyze mutations affecting receptor function. Additionally, these proteins aid in structural studies (e.g., cryo-EM) to resolve receptor-ligand binding mechanisms. Overall, CHRNb2 recombinant proteins bridge molecular insights with translational applications in drug discovery and neuropathology.
×
